Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 51 peer-reviewed journal articles Updated
Neonatology

Understanding Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

At a Glance

Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a rare condition where a mother's immune system attacks her baby's platelets, causing bruising and bleeding risks. It often occurs without warning in a first pregnancy, but babies typically recover quickly with proper NICU treatment.

Learning that your newborn has a serious medical condition can be overwhelming, especially when it happens without warning. Many parents first hear the term Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) when their baby is born with unexpected bruising or small purple spots on the skin [1][2]. While this news is a shock, understanding the biology of what is happening can help you navigate the next steps with your care team.

This guide is designed to empower you with evidence-based information so you can partner with your doctors to make the best decisions for your baby and your family’s future.

For more detailed information, please review the following sections:

01

The Biology of FNAIT: How and Why It Happens

Understand the biology behind Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Learn how HPA antigen mismatches affect your baby's platelets.

02

Recognizing and Diagnosing FNAIT in Your Newborn

Learn how Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is diagnosed in newborns. Understand symptoms like petechiae, ICH risks, and genetic testing.

03

Treating and Monitoring Your Baby with FNAIT

Learn about treating and monitoring your baby with FNAIT. Understand platelet transfusions, IVIG, breastfeeding safety, and follow-up care for low platelets.

04

FNAIT and Future Pregnancies: Risk, Screening, and Treatment

Learn how to manage FNAIT in future pregnancies. Understand paternal genotyping, NIPT screening, and proactive IVIG treatment to protect your next baby.

What is FNAIT?

FNAIT is an alloimmune disorder—a situation where a person’s immune system reacts against “foreign” cells from another person of the same species [2]. In this case, a mother’s immune system creates antibodies that target her baby’s platelets [3][4].

To understand FNAIT, it helps to define a few key terms:

  • Platelets: Small, colorless cell fragments in the blood that help the body form clots to stop bleeding [5][6].
  • Thrombocytopenia: The medical term for a low platelet count [5].
  • Human Platelet Antigens (HPA): Specific proteins found on the surface of platelets. A baby inherits these proteins from both parents [7][5].

FNAIT happens when the baby inherits a specific HPA from the father that the mother does not have. The mother’s immune system identifies these “paternal” proteins as foreign and produces antibodies (protective proteins) to attack them [5][8]. These antibodies cross the placenta, enter the baby’s bloodstream, and cause the baby’s platelets to be destroyed [3][2].

Why Did This Happen Without Warning?

Parents are often surprised because FNAIT frequently occurs during a first pregnancy [1][2]. This is different from other immune conditions, like Rh disease, which usually only affect second or later pregnancies.

In FNAIT, the mother can become “sensitized” (start making antibodies) very early in the first pregnancy, sometimes as early as the first trimester [1][2]. Because there is currently no universal screening for FNAIT, most families have no way of knowing it is occurring until the baby is born with symptoms [9][2].

Three Stabilizing Facts for Parents

If you are currently in the hospital processing this diagnosis, keep these facts in mind:

  1. FNAIT is Rare: It occurs in approximately 1 in 800 to 2,000 live births [9][2]. While it feels personal and sudden, medical teams in neonatal intensive care units (NICUs) have established protocols to manage it [10][11].
  2. Platelet Counts Usually Recover Quickly: Once a baby is born and no longer receiving the mother’s antibodies through the placenta, their body can begin to stabilize. With prompt treatment—which may include platelet transfusions or Intravenous Immunoglobulin (IVIG)—platelet counts often normalize rapidly [10][12].
  3. Future Pregnancies are Highly Manageable: If you choose to have more children, the “surprise” element is gone. Doctors can provide highly effective treatments (like IVIG) to the mother during future pregnancies, which significantly reduces the risk of complications for the next baby [13][14].

Incidence and Frequency

While the most common cause of severe FNAIT in Caucasian populations involves a specific protein called HPA-1a, other antigens may be involved depending on your genetic background [15][16]. Regardless of the specific antigen, the focus for your medical team right now is ensuring your baby’s platelet levels reach a safe range to prevent internal bleeding [17][10].

Most babies with FNAIT do not experience serious long-term health issues if the condition is identified and managed promptly after birth [13][17]. Your care team will likely use imaging, such as an ultrasound, to ensure there is no bleeding and monitor your baby’s blood work closely until they are out of the “buffer zone” of low platelets [11][17].

Common questions in this guide

What is Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)?
FNAIT is a rare blood disorder where a mother's immune system produces antibodies that mistakenly attack and destroy her baby's platelets. This results in a low platelet count for the newborn, which can cause bruising or bleeding.
Why did my baby get FNAIT without any warning?
Unlike some other immune conditions during pregnancy, FNAIT frequently happens during a first pregnancy and can develop as early as the first trimester. Because there is currently no universal routine screening for FNAIT, most parents only find out when their baby is born with symptoms.
What are the signs of FNAIT in a newborn?
The most common visible signs of FNAIT are unexpected bruising or small purple and red spots on the skin called petechiae. Doctors will also check for a low platelet count through blood tests and monitor for any signs of internal bleeding.
How is FNAIT treated after birth?
Once the baby is born, they no longer receive the mother's antibodies, and their platelet counts often stabilize quickly. Treatments to help them recover safely in the NICU may include platelet transfusions or intravenous immunoglobulin (IVIG).
Will FNAIT affect my future pregnancies?
If you have had a baby with FNAIT, there is a risk it could happen in future pregnancies. However, doctors can provide highly effective treatments like IVIG during your next pregnancy to significantly reduce the risk of complications for the baby.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my baby's lowest platelet count, and what is the current target count for a safe discharge?
  2. 2.Has a cranial ultrasound or other imaging been performed to check for internal bleeding (intracranial hemorrhage)?
  3. 3.Who is the pediatric hematologist or specialist who will be managing my baby's follow-up care?
  4. 4.Which specific Human Platelet Antigen (HPA) was involved, and can we have the father tested for this antigen as well?
  5. 5.If we plan for another pregnancy, what is the specific protocol for maternal treatment (like IVIG) to prevent this from happening again?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia.

    Curtis BR

    British journal of haematology 2015; (171(5)):671-82 doi:10.1111/bjh.13639.

    PMID: 26344048
  2. 2

    From concept to practice: Screening for fetal and neonatal alloimmune thrombocytopenia (FNAIT).

    Pothof R, de Vos TW, Lopriore E, et al.

    Best practice & research. Clinical obstetrics & gynaecology 2025; (103()):102683 doi:10.1016/j.bpobgyn.2025.102683.

    PMID: 41161115
  3. 3

    Fetal and neonatal alloimmune thrombocytopenia.

    Zdravic D, Yougbare I, Vadasz B, et al.

    Seminars in fetal & neonatal medicine 2016; (21(1)):19-27.

    PMID: 26810319
  4. 4

    Implication of antibodies against human leukocyte antigen in simultaneous presentation of fetal and neonatal alloimmune thrombocytopenia and neutropenia.

    Gimferrer I, Teramura G, Gallagher M, et al.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2018; (57(6)):773-776 doi:10.1016/j.transci.2018.09.018.

    PMID: 30318177
  5. 5

    Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61.

    Regan F, Lees CC, Jones B, et al.

    BJOG : an international journal of obstetrics and gynaecology 2019; (126(10)):e173-e185 doi:10.1111/1471-0528.15642.

    PMID: 30968555
  6. 6

    Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotyping.

    Hayashi T, Hirayama F

    Blood transfusion = Trasfusione del sangue 2015; (13(3)):380-90 doi:10.2450/2015.0275-14.

    PMID: 26057488
  7. 7

    Persistent neonatal alloimmune thrombocytopenia caused by triple anti-HLA-A11, -B3901, and -Cw7 antibodies.

    Hatano S, Maeda H, Ichikawa H, et al.

    International journal of hematology 2025; (121(6)):866-871 doi:10.1007/s12185-025-03968-4.

    PMID: 40159572
  8. 8

    Taking a wider view on fetal/neonatal alloimmune thrombocytopenia.

    Bonstein L, Haddad N

    Thrombosis research 2017; (151 Suppl 1()):S100-S102 doi:10.1016/S0049-3848(17)30078-6.

    PMID: 28262226
  9. 9

    [Management of high-risk pregnancies in a context of maternal antiplatelet alloimmunization: Expert opinion of the French-speaking working group].

    Bertrand G,

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2021; (28(4)):370-374 doi:10.1016/j.tracli.2021.08.349.

    PMID: 34464715
  10. 10

    Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach.

    Lieberman L, Greinacher A, Murphy MF, et al.

    British journal of haematology 2019; (185(3)):549-562 doi:10.1111/bjh.15813.

    PMID: 30828796
  11. 11

    Subamniotic Hemorrhage, a Possible New Presentation of Fetal and Neonatal Alloimmune Thrombocytopenia.

    Giesbers S, Bos M, Bulten J, et al.

    Fetal diagnosis and therapy 2022; (49(1-2)):60-64 doi:10.1159/000521866.

    PMID: 35021176
  12. 12

    Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies.

    Winkelhorst D, Oepkes D, Lopriore E

    Expert review of hematology 2017; (10(8)):729-737 doi:10.1080/17474086.2017.1346471.

    PMID: 28644735
  13. 13

    Long-term neurodevelopmental outcome in children after antenatal intravenous immune globulin treatment in fetal and neonatal alloimmune thrombocytopenia.

    de Vos TW, de Haas M, Oepkes D, et al.

    American journal of obstetrics and gynecology 2022; (227(4)):637.e1-637.e9 doi:10.1016/j.ajog.2022.05.063.

    PMID: 35671780
  14. 14

    Fetal and Neonatal Alloimmune Thrombocytopenia: Management and Outcome of a Large International Retrospective Cohort.

    Kamphuis MM, Tiller H, van den Akker ES, et al.

    Fetal diagnosis and therapy 2017; (41(4)):251-257 doi:10.1159/000448753.

    PMID: 27728915
  15. 15

    Neonatal alloimmune thrombocytopenia due to anti-HPA 5a in a HPA-5a homozygous neonate.

    Porta R, Serrano P, Paltrinieri A, et al.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(6)):102880 doi:10.1016/j.transci.2020.102880.

    PMID: 32763115
  16. 16

    Severe neonatal thrombocytopenia due to anti-HPA-4b alloantibodies: Third report described in a Caucasian mother.

    Petermann R, Bianchi F, Saib L, et al.

    Transfusion 2024; (64(6)):1167-1170 doi:10.1111/trf.17863.

    PMID: 38693097
  17. 17

    Cerebral vasculature exhibits dose-dependent sensitivity to thrombocytopenia that is limited to fetal/neonatal life.

    Farley AM, Dayton M, Biben C, et al.

    Blood 2022; (139(15)):2355-2360 doi:10.1182/blood.2021014094.

    PMID: 35148538

This page provides educational information about FNAIT for parents and caregivers. It does not replace professional medical advice from your baby's neonatologist or pediatric hematologist.

Get notified when new evidence is published on Fetal and neonatal alloimmune thrombocytopenia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.